CBD a Nutraceutical Ingredient of the Future

The expanding market of hemp derived products represents a business opportunity for all health and wellness manufacturers. At Endoca, we are proud to deliver top quality organic, pharmaceutical-grade hemp extracts with CBD.


CBD (Cannabidiol) is one of over one hundred compounds found the hemp plant called cannabinoids. It is currently the subject of extensive scientific research which show the compound to be a natural painkiller thanks to its anti-inflammatory properties. Not only that, studies have also found CBD to have an anti-anxiety, calming effect, as well as being a potent antioxidant.

Pharmaceutical Grade CBD

Endoca prides itself on the purity of its CBD products, which come from 100% organic certified hemp grown in the EU. We employ Good Manufacturing Practices (GMP) and third party lab testing to ensure that ours are the cleanest, highest quality hemp extracts with CBD on the market. We use a CO2 critical extraction method to preserve the active ingredients from the hemp plant.

Bulk and wholesale options available

Partner with us to scale-up your process or product development pipeline with special pricing on bulk quantities of our high quality (CBD) cannabinoid oils (up to 99% CBD).

Go to article: Home | Getting PersonalGo to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: In this issueGo to article: International Cannabis and Cannabinoid Institute (ICCI) Company InsightGo to article: International Cannabis and Cannabinoid Institute (ICCI)Go to article: ContentsGo to article: Novo NordiskGo to article: NewsGo to article: PhoenixGo to article: The Pharma Industry BriefingGo to article: Nelson Lab Company InsightGo to article: Nelson LabsGo to article: Manufacturing personalised meds: what needs to change?Go to article: Molnar Company InsightGo to article: MolnarGo to article: Selling cells: the economics of CAR-T therapyGo to article: Wilhelm Haselmeier GmbH & Co KG Company InsightGo to article: Wilhelm Haselmeier GmbH & Co. KGGo to article: Using AI to personalise drug combination therapyGo to article: NSFGo to article: Is the microbiome as important for precision medicine as genetics?Go to article: Nipro PharmaPackagingGo to article: A summer of manufacturing disasters for Chinese pharmaGo to article: CapsugelGo to article: EndocaGo to article: ContraFect’s Staph infection drug may succeed in trial but caveats remainGo to article: Dow Europe GmbH Company InsightGo to article: Dow Europe GmbHGo to article: Why are novel therapies for glioblastoma patients not gaining approvals?Go to article: Lubrizol Life SciencesGo to article: QualiMetriXGo to article: CAR-T approved in Europe but NICE verdict is divided: what happens next?Go to article: Palleos healthcare GmbH Go to article: Daiichi JitsugyoGo to article: EventsGo to article: Nemera Company InsightGo to article: Erdmann Design SwitzerlandGo to article: Next issueGo to article: NemeraGo to article: Plastiape Go to article: General Electric Healthcare